HS-IT101 Injection

DRUG2 trials

Sponsors

Qingdao Sino-Cell Biomedicine Co., Ltd.

Conditions

Advanced MelanomaSolid Tumor

Phase 1

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

RecruitingNCT06342336

Qingdao Sino-Cell Biomedicine Co., Ltd.Solid Tumor

Start: 2024-01-18End: 2028-03-31Target: 44Updated: 2024-04-02

HS-IT101 Injection in the Treatment of Advanced Melanoma

Enrolling by invitationNCT06941818

Qingdao Sino-Cell Biomedicine Co., Ltd.Advanced Melanoma

Start: 2025-07-10End: 2027-05-30Target: 10Updated: 2025-08-14

Related Papers

Abstract CT195: Fast-manufactured, low IL-2-dependent FAST-TIL for the treatment of advanced melanoma in asian patients: Median 6-month follow-up data from a phase I clinical trial

Cancer Research2026-04-17

Autologous tumor-infiltrating lymphocytes (HS-IT101) with low-dose lymphodepletion and IL-2 infusion for the treatment of advanced solid tumors: A phase I clinical trial.

Journal of Clinical Oncology2025-05-281 citations

Abstract CT114: FAST TIL: A more effective cell therapy product with great potential for the treatment of solid tumors

Cancer Research2025-04-25